Rivastigmine and concomitant memantine in alzheimer's disease: Safety and tolerability

CNS Spectrums

Volumn 15, Issue 9, 2010, Pages 594-598

  Safirstein, Beth ^a   Meng, Xiangyi ^b   Olin, Jason T ^b  

^a Clinical in Hallandale Beach   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; MEMANTINE; RIVASTIGMINE;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ANGINA PECTORIS; ANXIETY; APPLICATION SITE REACTION; ARTICLE; ASTHENIA; BRADYCARDIA; CARDIOGENIC SHOCK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FALLING; FEMALE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; INSOMNIA; LETHARGY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SYNCOPE; TRANSDERMAL PATCH; UNCONSCIOUSNESS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VITAL SIGN; VOMITING; WEIGHT REDUCTION;

EID: 77957364812     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900000572     Document Type: Article

References (10)

1. Exelon Capsule. Prescribing Information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf. 2001. Accessed: August 2010.
2. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318(7184):633-638.
3. Olin J, Bhatnagar V, Reyes P, Koumaras B, Meng X, Brannan S. Safety and tolerability of rivastigmine capsules with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial. Int J Geriatr Psychiatry. 2010;25(4):419-426.
4. Exelon transdermal patch. Prescribing information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf. 2007. Accessed: August 2010.
5. Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14-22.
6. Sadowsky C, Dengiz A, Olin J, Koumaras B, Meng X, Brannan S. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Am J Alzheimer Dis Other Demen. 2009;Epub 16 March:doi: 10.1177/1533317509333037.
7. Folstein MF, Folstein SE, McHugh PR. ''Mini-mental state''. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
8. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text rev. Washington, DC: American Psychiatric Association; 1994.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
10. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22(5):456-467.